Open AccessCardiovascular Manifestations of Systemic Sclerosis: A Danish Nationwide Cohort Study
Author(s) -
Butt Sheraz A.,
Jeppesen Jørgen L.,
TorpPedersen Christian,
Sam Flora,
Gislason Gunnar H.,
Jacobsen Søren,
Andersson Charlotte
Publication year - 2019
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.119.013405
Subject(s) - medicine , hazard ratio , myocardial infarction , dyslipidemia , stroke (engine) , population , incidence (geometry) , proportional hazards model , cardiology , cohort , heart failure , disease , confidence interval , mechanical engineering , physics , environmental health , optics , engineering
Background Cardiovascular involvement in systemic sclerosis ( SS c) comprises a wide range of manifestations with prevalence and incidence that remain uncertain. Methods and Results In the Danish administrative registries between 1995 and 2015, all patients aged ≥18 years with a first diagnosis of SS c were matched by age and sex with controls (1:5) from the general population. Prevalence of cardiovascular diseases at the time of the SS c diagnosis and incidence during follow‐up were assessed by in‐ and outpatient discharge diagnoses. Conditional logistic and Cox proportional hazards regression models were used respectively to calculate odds ratios for prevalent cardiovascular diseases and hazard ratios ( HRs ) for incident diseases associated with SS c. Patients with SS c (n=2778; 76% women; mean±SD age: 55±15 years) had more established cardiovascular risk factors than their respective controls at baseline, including greater prevalence of hypertension (31.2% versus 21.0%, P <0.0001) and treated dyslipidemia (9.8% versus 8.5%, P =0.02). SS c was associated with an increased relative risk of developing most cardiovascular diseases, including myocardial infarction (HR: 2.08; 95% CI, 1.65–2.64), peripheral vascular disease (HR: 5.73; 95% CI, 4.63–7.09), pulmonary hypertension (HR: 21.18; 95% CI, 14.73–30.45), mitral regurgitation (HR: 4.60; 95% CI, 3.12–6.79), aortic regurgitation (HR: 3.78; 95% CI, 2.55–5.58), aortic stenosis (HR: 2.99; 95% CI, 2.25–3.97), pericarditis (HR: 8.78; 95% CI, 4.84–15.93), heart failure (HR: 2.86; 95% CI, 2.43–3.37), atrial fibrillation (HR: 1.75; 95% CI, 1.51–2.04), and venous thromboembolism (HR: 2.10; 95% CI, 1.65–2.67). Additional adjustment for medications and comorbidities yielded results similar to the main analyses. Conclusions In this nationwide study, SS c was associated with greater risks of distinct cardiovascular diseases for patients than for matched controls, suggesting a significant disease‐related adverse impact across the vascular bed and specific cardiac structures.